 | • レポートコード：MRC2106A394 • 出版社/出版日：Mordor Intelligence / 2021年5月30日 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査資料は、世界の細胞治療市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、種類別（自己、同種）分析、治療別（間葉系幹細胞治療、線維芽細胞治療、造血幹細胞治療、その他）分析、用途別（筋骨格、悪性腫瘍、心血管、皮膚科・創傷、その他）分析、地域別分析、競争状況、市場機会/将来の見通しなどを掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の細胞治療市場規模：種類別（自己、同種） ・世界の細胞治療市場規模：治療別（間葉系幹細胞治療、線維芽細胞治療、造血幹細胞治療、その他） ・世界の細胞治療市場規模：用途別（筋骨格、悪性腫瘍、心血管、皮膚科・創傷、その他） ・世界の細胞治療市場規模：地域別 ・競争状況 ・市場機会/将来の見通し |
The Cell Therapy Market is expected to grow with a CAGR of 6.8% over the forecast period.
The impact of the COVID-19 pandemic on the cell therapy market is expected to be significant as most of the companies have been focusing on the development of cell-based therapies for COVID-19 treatment. For instance, in April 2020, Calidi Biotherapeutics, Inc., revealed that the Investigational New Drug (IND) application submitted by its partner, Personalized Stem Cells, Inc. (PSC), has received FDA approval for the treatment of COVID-19 and pneumonia patients using stem cell therapy. The impact of COVID-19 is also expected to show a positive impact on the studied market as most of the pharmaceutical, biotechnology, and research institutes have been focusing on the development of cell therapy-based treatment against COVID-19. For instance, in November 2020, Novartis obtained the license for the Mesoblast’s cell therapy remestemcel-L for the treatment of COVID-19. Thus, owing to the rising research activities pertaining to the development of cell therapies in treating SARS-CoV2 infection, the studied market is expected to impact during the COVID-19 pandemic era.
The cell therapy market is anticipated to witness healthy growth due to the increasing prevalence of chronic conditions, rising adoption of regenerative medicine, and rise in the number of clinical studies about the development of cellular therapies.
Chronic diseases and conditions are on the rise worldwide. According to the Global Alliance for Chronic Diseases (GACD) 2018, one in ten individuals is predicted to have type 2 diabetes by 2035 worldwide and is predicted to be the 7th leading cause of death by 2030. Also, according to Globocan 2020, the new cancer cases that were diagnosed accounted for 19,292,789 in 2020 worldwide, with 9,958,133 deaths due to cancers globally. Among all cancers, breast cancer accounted for 2,261, 419 new cancer cases, followed by lung (2,206,771), Prostate (1,414,259) and colon (1,148,515) new cases in 2020.Additionally, as per the International Diabetes Federation Diabetes Altas Ninth Edition 2019, nearly 463 million population globally are living with diabetes worldwide and are expected to reach 700 million by 2045. Therefore the increasing prevalence of chronic conditions, along with the government assistance and numerous companies investing heavily in stem cell therapy research and development is predicted to help to stimulate industry growth. The proven effectiveness of cell therapy products coupled with increasingly favorable guidelines on cell therapy research and manufacturing also aids in the positive impact of the studied market over the forecast period.
Key Market Trends
Allogeneic Therapies Segment is Expected to Account for the Largest Share in the Cell Therapy Market
Allogeneic therapies rely on a single source of cells to treat many patients. They increase the risk of eliciting an immune response within a patient, and immunosuppressive therapies are sometimes administered in combination with allogeneic products. Therefore the increasing inclination of physicians towards therapeutic use of allogeneic therapies coupled with rising awareness about the use of cord cells and tissues across various therapeutic areas are some of the major factors driving the growth. Allogenic cells have benefits as they produce their own immune stem cells, that kill the cancer cells that remain even after high-dose treatment with cytotoxic drugs. This response is called a graft-versus-cancer effect and this is used in the prevention or treatment of cancer relapse. The aforementioned factors are expected to drive the market over the forecast period.
Moreover, cancer recurrence is a foremost concern of patients and their caregivers. Fear of recurrence can negatively affect the quality of life, and as per the “cancer recurrence statistics” published in 2018, approximately 7% of patients develop severe and disabling fear that includes constant intrusive thoughts and misinterpretation of mild and unrelated symptoms. These recurrences are usually observed in children and patients suffering from breast and oropharyngeal cancer. Allogenic transplantation is recommended for patients with a high risk of relapse after successive courses of induction chemotherapy. Thus, an increase in the incidence of cancer relapse has provided growth avenues to the demand for allogeneic therapies. Furthermore, the rising number of clinical trials which are required to gain regulatory approval for new medications to advance patient care is expected to boost the segment growth. For instance, ALLO-501, ALLO-501A, ALLO-715, UCART19, and UCART19 by Allogene is providing growth opportunities to the segmental growth. Thus, owing to the rising number of research on allogenic therapy for cancer, and associated benefits, the studied segment is anticipated to register steady growth over the forecast period.
North America is Expected to Dominate the Market Over the Forecast Period
North America is estimated to retain the largest share of the Cell Therapy market due to the presence of a strong regulatory framework to promote cellular therapy development, the existence of industry key players, and also the presence of leading universities that supports the research activities in the United States. Also, the factors attributing to the high growth of the studied market in the region include the increasing prevalence of chronic conditions, rising adoption of regenerative medicine, and rise in the number of clinical studies about the development of cellular therapies.
There is a tremendous amount of funding in the United States available, to increase Research and Development activities in the field of cancer. As per the data published by the National Cancer Institute (NCI), in 2019, the Department of Defense and Labor, the Department of Health and Human Services, and the Education Appropriations Act allotted USD 5.74 billion to the NCI, which indicated a USD 79 million increase over FY 2018. As cell therapies have huge potential in treating cancer, the availability of funding is expected to further help in overall market growth. In July 2020, US FDA approved Tecartus (brexucabtagene autoleucel) which is a cell-based gene therapy for the treatment of mantle cell lymphoma (MCL). Also, in July 2020, FDA has approved Talaris Therapeutics, Inc., an investigational new drug application for the evaluation of Talaris’ novel cell therapy FCR001 in the treatment of diffuse systemic sclerosis (SSC). Moreover, as per the Regulatory Affairs Professionals Society, in 2019 USFDA has granted 34 designations associated with regenerative medicine advanced therapy wherein 68 out of 100 are cell therapy products. The rising adoption of regenerative medicines and related clinical studies in the region is thus anticipated to propel the market growth over the forecast period.
Competitive Landscape
The Cell therapy market is moderately competitive and has a presence of a considerable number of companies. The major companies of the studied market are Pharmicell Co., Ltd., Corestem, Inc., Chiesi Farmaceutici S.p.A., Tegoscience, Anterogen Co., Ltd., TiGenix (Takeda Pharmaceuticals), Stempeutics Research Pvt. Ltd., Nipro Corporation, Medipost Co., Ltd among others. These companies are evolving through various strategies such as investment in research and development, acquisitions, partnerships, and collaboration to secure the market position. For instance, in Jan 2020, Allogene Therapeutics, Inc. and SpringWorks Therapeutics, Inc announced a clinical trial collaboration agreement for the evaluation of ALLO-715 along with Nirogacestat in Multiple Myeloma patients.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Chronic Conditions
4.2.2 Rising Adoption of Regenerative Medicine
4.2.3 Rise in Number of Clinical Studies Pertaining to the Development of Cellular Therapies
4.3 Market Restraints
4.3.1 High Cost of Therapies
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Autologous
5.1.2 Allogeneic
5.2 By Therapy
5.2.1 Mesenchymal Stem Cell Therapy
5.2.2 Fibroblast Cell Therapy
5.2.3 Hematopoietic Stem Cell Therapy
5.2.4 Other Therapies
5.3 By Application
5.3.1 Musculoskeletal
5.3.2 Malignancies
5.3.3 Cardiovascular
5.3.4 Dermatology & Wounds
5.3.5 Other Applications
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Anterogen Co., Ltd.
6.1.2 Tego Science
6.1.3 Chiesi Farmaceutici S.p.A.
6.1.4 Corestem Inc.
6.1.5 Pharmicell Co Ltd.
6.1.6 Fibrocell Technologies Inc
6.1.7 Nipro Corporation
6.1.8 MEDIPOST Co., Ltd
6.1.9 TiGenix (Takeda Pharmaceuticals)
6.1.10 Stempeutics Research Pvt. Ltd.
6.1.11 Gilead Sciences, Inc. (Kite Pharma, Inc.)
6.1.12 Allogene Therapeutics, Inc.
6.1.13 Novartis AG
6.1.14 Vericel Corporation
6.1.15 Organogenesis, Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS